Poor Agreement for Practitioners in Defining Myofascial Pain

This article originally appeared here.
Share this content:
Poor Agreement for Practitioners in Defining Myofascial Pain
Poor Agreement for Practitioners in Defining Myofascial Pain

FRIDAY, Dec. 1, 2017 (HealthDay News) -- Health care practitioner groups differ regarding the signs and symptoms that define myofascial pain syndrome (MPS), according to a study published online Nov. 1 in PAIN Practice.

Yasmin Nasirzadeh, from the University of Toronto, and colleagues surveyed 337 health care practitioners to assess their agreement with the chosen signs and symptoms of MPS using a seven-point agreement scale. Intraclass correlation within chiropractor, physician, and registered massage therapy groups was used to assess agreement.

The researchers observed poor agreement among chiropractors, physicians, and registered massage therapists on the criteria that define MPS. Physicians and massage therapists agreed on four items and disagreed on two items; chiropractors agreed on a different set of signs and symptoms than physicians and registered massage therapists, and expressed neutrality on most statements. Compared with chiropractors and physicians, registered massage therapists were most in agreement as a group.

"Our results suggest that there is a lack of agreement within and between health care practitioner groups on the signs and symptoms that define myofascial pain syndrome," the authors write. "We suggest the demonstrated variability in diagnostic knowledge be remedied through the establishment and universal use of official validated criteria."

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »